PanGenex Enters Into Strategic Partnership With BulovaTech

PanGenex has entered into a strategic partnership with BulovaTech Labs (LABS), a wholly-owned subsidiary of Bulova Technologies Group. The new partnership supports the joint development and commercialisation of PanGenex’s nutraceutical and healthcare products.

Reportedly, the partnership includes an exclusive collaboration agreement that will accelerate the development of proprietary technologies and products, which will be marketed by PanGenex under the PanGenex trademark.

Jim Mosbaugh, COO of PanGenex, said: “BulovaTech Labs is an ideal partner for PanGenex. Through LABS’ parent company, Bulova Technologies Group, LABS has access to substantial technical and financial resources. Together, we can continue to drive momentum for sales of unique, condition-specific, and proven effective nutraceutical and healthcare products worldwide.”

John Stanton, chairman of BulovaTech, said: “LABS is an exciting venture that seeks to invest in high-growth ground floor opportunities, including the rapidly growing market for nutraceuticals. We are confident that by collaborating with PanGenex we can rapidly bring successful commercial products to markets worldwide.”